Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors
NCT01694472
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Malignant Solid Tumors
Interventions
BIOLOGICAL:
MAGE-A4 TCR Gene-Modified T Cells
Sponsor
Tianjin Medical University Cancer Institute and Hospital